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ABSTRACT
Linear dendritic block copolymers are amphiphilic molecules that consist of a dendritic
hydrophilic portion and a linear hydrophobic portion. Its unique ability to self-assemble into
spherical nanoaggregates while having the potential to uptake and transport both hydrophilic and
hydrophobic drugs makes these polymers an item of interest in regard to the drug delivery field.
The synthesis of polyamidoamine-polylactide linear dendritic block copolymers was designed to
address the common issues in drug delivery systems, including problems in permeability,
solubility, stability, specificity, and retention. Though this linear dendritic block copolymer has
previously been synthesized in our lab with cationic amine surface functionalities, this study dives
deeper into the potential of these polymers by synthesizing a dendritic segment with varying
surface functionalities: carboxylate and alcohol. The hydrophobic polylactide portion of the
copolymer is connected to the hydrophilic PAMAM portion through ring-opening polymerization
(ROP) with a weight percentage of 70 with regard to the polylactide portion. The synthesis of these
two molecules were completed in this study and confirmed through NMR. The size, morphology,
and charge of the self-assembled nanoparticles were analyzed through the use of electron
microscopy, dynamic light scattering, and zeta potential values. The results of this study show the
potential of these nanoparticles to make an impact in biomedical applications.
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INTRODUCTION
With more than 10 million new cases each year, cancer-related deaths are projected to
increase in the near future with an estimation by the World Health Organization of 13.1 million
cancer-related deaths by the year 2030.1 However, the mortality rate has decreased in recent years
due to a better understanding of tumor biology and improved diagnostic devices and treatment.
Specifically, innovative drug delivery systems are being designed to improve targeting directly to
tumor cells by drugs. There have also been improvements in maintaining the stability of the drug
carrier, which allows drugs to remain at a therapeutic concentration over longer periods of time.
Composed of versatile materials including inorganic carriers, polymeric hydrogels, bio
macromolecular scaffold, lipids, and polymers, these drug delivery systems have the potential to
aid cancer treatment in multiple ways like facilitating cancer prevention and assisting in pain
management.2–4 There is an added benefit with the use of nanoscale drug delivery systems, which
can include enhanced permeability, solubility, stability, and retention as well as its miniaturization
status, making it possible for the creation of devices for use as diagnostics, biosensors, and imaging
agents.2,5,6 Interestingly, a significant subset of existing drug delivery systems are those based on
polymers.7
One particular polymer family of interest is polyamidoamine (PAMAM) which is shown
in Figure 1. First described in great detail and termed a dendrimer in 1984 at the first International
Polymer Conference, Society of Polymer Science in Japan, PAMAM dendrimers are a unique class
of highly branched, spherical, and symmetrical polymers that are highly soluble in aqueous
solutions.8 Composed of repetitive branched subunits of amide and amine functionality, its
structure can be divided into 3 regions: core, interior (branches), and exterior (end groups). The
number of branching points encountered upon moving outward from the core of the dendrimer to

1

its periphery defines its generation (G1, G2, G3). The stepwise, divergent synthesis of this
dendrimer allow the precise control of size, shape, and placement of functional groups, which
yields a high degree of molecular uniformity and low polydispersity, making them suitable for
biomedical and drug delivery applications.8,9 For every increase in generation, the number of
functional groups doubles, while the dendrimer diameter increases by about 1 nm.10 Compared
with many other types of dendritic macromolecules that have recently been synthesized, PAMAM
dendrimers are undispersed and show high positive charge densities restricted to the surface of the
molecule as shown due to the terminal amine groups.11,12

Figure 1: The three regions of the PAMAM dendrimer is shown. Though the core in this example is a
cystamine core, a variety of different cores are possible including ammonia and ethylenediamine.13

Despite having many well-defined properties, this polymer has several limitations for
biomedical applications, such as rapid systemic clearance12, significant toxicological issues
associated with its cationic feature14 , poor drug loading, and difficulty in achieving controlled
2

drug release.15 To overcome the drawbacks of the symmetrical conventional dendrimer, alterations
in its structure, including modifications to its surface, have been reported.16
Janus dendrimers are a specific alternative to the symmetrical dendrimer and are
characterized by two differently functionalized segments on opposite sides. Amphiphilic Janus
dendrimers, which consist of hydrophobic and hydrophilic dendrons, are being considered in drug
delivery systems as a result of their ability to self-assemble into complex supramolecular structures
under certain conditions into morphologies including polymeric micelles, vesicles, and multilayered structures in aqueous solutions.17 Ideal properties of these dendrimers is that they may
prolong the circulation time, reduce the uptake of drugs by the reticuloendothelial system (RES),
and have the potential to assume two, or even more, different tasks such as targeting a particular
site and transporting a medicinally active drug to this site.10
In addition to Janus dendrimers, linear dendritic block copolymers (LDBCs) are also
composed of differently functionalized segments on opposite sides and have great significance as
drug delivery systems. As opposed to Janus dendrimers, which are composed of two dendritic
backbones linked together, LDBCs are composed of a dendritic portion combined with a linear
portion. LDBCs were developed with the purpose of combining the unique structural properties of
dendrimers with the versatility and simplicity of linear block copolymers.18 These polymer form
nanoparticles with high hydrophobic drug loading capabilities while maintaining the
multifunctional nature of the dendritic scaffold. The drug loading of Janus dendrimers has been
primarily limited to use with drugs that can be chemically conjugated, which is the same weakness
of dendrimers. This limited versatility of dendrimers carrying chemically unreactive drug
molecules can be overcome by engineering LDBCs that combine a dendritic scaffold with one or
more linear polymers. It maintains the benefit of having a symmetrically branched portion from
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the inclusion of the PAMAM dendrimer with a well-defined number of end groups that offer
versatility to the macromolecules by applying a variety of surface chemistries and architectural
engineering to tunes their physiochemical and biological properties.15

Figure 2: The different architectures of the dendritic polymers include (A) dendrimer type; (B) linear dendritic
block copolymers; and (C) Janus dendritic polymer. The core of the dendrimer is in red, the branches of PAMAM
dendrimer are in pink, the terminal groups are in blue, the linear polymeric chain is in navy, and another type of
dendron with different functional groups is in orange.19

Previously, we investigated LDBCs composed of the branched hydrophilic PAMAM
moiety with terminal amine groups and linear hydrophobic polylactide moiety. The weight ratio
(wt%) of the hydrophobic to hydrophilic portion was manipulated to observe the changes in
morphology and size; however, surface functionalization was not discussed. To further expand on
this study, our goal is to synthesize LDBCs with varying terminal functional groups on the
PAMAM moiety to minimize the current problems seen in polymeric drug delivery systems while
capitalizing on the unique properties for applications in biomedical research.
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SCIENTIFIC RATIONALE
Of the options of polymers and dendrimers used in nanotechnology, PAMAM has many
benefits that make its use promising in drug delivery. It has been well studied and characterized in
literature and has the unique properties of having a three-dimensional architecture, a
multifunctional surface, internal cavities, and a nanometric size range that facilitate and modulate
drug delivery. It also has easily modifiable terminal end groups, which allow for our desired
modification.20
Though PAMAM has many of these benefits, the dendrimer cell toxicity is a concern. In
fact, some of the first cationic dendrimers synthesized were found to be extremely toxic to cells in
vivo. This is largely attributed to the interactions between the negatively charged biological
membranes and the high positive surface charge density of cationic dendrimers. The toxicity of
cationic PAMAM dendrimers, such as those with 100% amine surfaces, is well recorded and
studies show increasing toxicity with each succeeding generation. Though a slightly positive
charge allows for interaction between the drug delivery system and the negative charge of the
cancerous cell, a large overall positive surface charge has been shown to cause lysis of blood cells.
Modifications to the surface of the PAMAM dendrimer surface can alter the cytotoxicity of the
nanomolecules and increase their biocompatibility.21 Therefore, in an attempt to reduce the surface
charge on the exterior groups on the PAMAM portion of the vehicle, the functionalization of the
terminal end groups with carboxylate or alcohol functional groups is considered. This addition
allows for the possibility of our molecules to be used as the starting material for the addition of
other biomarkers and allow for more modifications to increase the specificity of the drug treatment.
While PAMAM is used for the hydrophilic portion, the hydrophobic portion of the LDBC
is composed of a linear chain of polylactide. Polylactic acid (PLA), an important synthetic
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polyester, has been widely used in various biomedical applications due to its biodegradability
under physiological conditions, good biocompatibility, and excellent shaping and modeling
properties.22 It has a facile synthesis and is generally synthesized by ring-opening polymerization
(ROP) of lactic acid initiated with hydroxyl- and/or amine-functionalized initiators. This form of
polyester has low immunogenicity and good mechanical properties.23 The monomer, lactic acid,
contains an asymmetric alpha-carbon, typically described as the D or L form in classical
stereochemical terms. This means that the polymer chain exists in three forms: optically active
poly(L -lactide) and poly(D -lactide) and the racemic mixture of both enantiomers poly (DLlactide). The physicochemical properties of optically active D and L are nearly the same while the
racemic PLA has very different characteristics. For example, PLLA is highly crystalline while
racemic PLA is completely amorphous. 23,24
Herein, we introduce the novel PAMAM-DL-lactide hybrid dendrimer with a G3-PAMAM
moiety and linear DL-lactide moiety used in a 70% weight ratio. PAMAM has been chosen as the
hydrophilic portion due to the extensive research done on the dendrimer and its previously stated
benefits to drug delivery systems. Generation 3 of the dendrimer is being studied as it has been
shown that the open, flexible structure of low generation dendrimers and steric branch crowding
of high generation dendrimers provide less efficient encapsulation.25 As a starting point of
combining the mechanical and drug loading benefits of a linear PLA portion to dendritic PAMAM,
the poly (DL-lactide) form was chosen from the three enantiomer options. The 70-weight percent
ratio was chosen for this study because it has been shown that this weight ratio is the most stable
and produces the morphology of nanoparticles desired for the drug delivery system when
compared to the other weight ratios of 30, 50, and 90.
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This macromolecule has been successfully synthesized with two different terminal end
groups: anionic carboxylic acid and neutral alcohol. The data produced from the LDBCs that are
terminated with carboxyl and hydroxyl end groups is compared with data from the previously
studied amine terminal group. The resulting LDBCs are amphiphilic and have the ability to selfassemble into nanoparticles.

Figure 3: Structure of the linear dendritic block copolymers synthesized: DL-G3-OH and DL-G3-COOH.

The design and synthesis of these dendrimers are unique and novel in that they can be
modified with a variety of end groups. The exterior of the PAMAM moiety includes carboxylate
and alcohol functional groups. Each group has a protecting group that can be removed at the final
step in order to reduce the chance of unwanted side reactions. These protecting groups are tertbutyl ester (TBE), which protects the carboxylic acid, and tetrahydropyran (THP), which protects
the alcohol. The core of the PAMAM moiety includes a free unprotected hydroxyl group which is
used as an initiator of ROP to add the linear PLA chain.
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Overall, the new PAMAM-PLA LDBC shows potential as a drug delivery system to
improve issues in the realm of cancer treatment. Through comparative analysis, the polymers and
their aggregates will be studied to determine their usefulness in biomedical research.
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RESULTS AND DISCUSSION
DESIGN STRATEGY
To complete the synthesis of the desired polymers, the PAMAM portion is synthesized
first by alternating reactions of Michael additions and amidations using methyl acrylate and
ethylenediamine to create each increasing generation of the polymer. Using the divergent method,
an ethanolamine core is used as the starting point and grows the branches from the central
molecule. This process is done in a stepwise manner, leading to more control over the size and
number of branches on the hydrophilic portion of the final product. The core of the PAMAM
moiety contains a hydroxyl group to be used as a point of initiation for ROP. The first halfgeneration is made by a Michael addition between the core and methyl acrylate. The first full
generation is made by reacting the half generation with ethylenediamine through a nucleophilic
amidation. These steps are repeated until the PAMAM dendron reached Generation 2. Generation
2 PAMAM was treated with tertbutyl acrylate in methanol to obtain HO-PAMAM-G3-TBE with
a 92% yield. Generation 2.5 PAMAM was treated with ((tetrahydro-2H-pyran-2yl)oxy)methanamine in methanol to obtain HO-PAMAM-G3-THP with 89% yield.
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Figure 4: The structures of HO-PAMAM-G3-THP and HO-PAMAM-G3-TBE, respectively.

After the synthesis of the PAMAM portion, ROP is done. Before beginning the reaction,
the macroinitiators (PAMAM) are freeze-dried to ensure no water present. Under inert conditions,
DL-lactide monomer is combined with the G3 OH PAMAM under inert conditions in dry
chloroform and allowed to stir until dissolved. 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) is then
added as a catalyst for the reaction. The reaction is allowed to stir and checked through 1H NMR
hourly until there is confirmation that lactide starting material is completely reacted. The reaction
is then quenched through the addition of benzoic acid. The LDBCs were made with relatively high
yields for both dendrimers (89% for TBE and 92% for THP). Weight analysis of these molecules
was completed using nuclear magnetic resonance (NMR) spectroscopy and gel permeated
chromatography (GPC). The molar mass of the protected intermediates is calculated through the
use of 1H NMR spectroscopy. Tabulated results are provided in Table 1.
10

The protecting groups of the terminal ends of the PAMAM moiety, TBE and THP, were
removed using trifluoroacetic acid (TFA). The deprotection yields the final LDBCs: 70-DL-OH
and 70-DL-COO-.
Table 1: Molecular Weight Characterization of LDBCs by GPC with THF as the elution solvent.

Sample

MTh
g mol -1

NMR
Mw
g mol-1

Mn
g mol-1

GPCTHF
Mw
g mol-1

70-DL-TBE

4838

5738

8675

10 870

1.25

70-DL-THP

6230

5222

6031

8265

1.37

PDI

Mth, Mw, and Mn denote the theoretical molar mass, the weight average molar mass, and the number average molar
mass, respectively. The PDI refers to the distribution of the molecular weight of the LDBC. Notation of 70-DL denotes
LDBC composition where the DL PLA is linked to the G3 PAMAM portion with a weight percentage of 70% as
attributed to the PLA portion.
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SELF ASSEMBLY AND MORPHOLOGY
Table 2: DLS and Zeta Potential of Aggregates in Different Aqueous Media
Water
Sample

Intensity
(nm)

70-DL-

297.97/

OH

2716

70-DLCOO

-

333.03/
4607

PBS Buffer

Number
(nm)

PDI

Zeta
Potential
(mV)

214.93

0.321

+16.03

212.73

0.654

+4.88

Intensity
(nm)
161.7/
1533
220.86

Number
(nm)

PDI

Zeta
Potential
(mV)

131.5

0.779

-34.57

57.37

0.447

-25.50

The intensity, number, polydispersity index, and zeta potential are given for each LDBC in the solvents water and
phosphate-buffered saline (PBS).

Dynamic light scattering (DLS), zeta potential data and transmission electron microscope
imaging (TEM) were reported in order to demonstrate the LDBCs’ abilities to self-assemble and
its corresponding charge. Additionally, these results will provide insight on the effects of end
group variation. The self-assembly of the LDBCs was done in water and phosphate-buffered saline
(PBS) through nanoprecipitation. The use of PBS is beneficial in analysis of the nanoparticles due
to the solution having osmolarity and ion concentrations that match those of the human body. In
PBS, the carboxylate functional group is in its negatively charged state (COO-) while the hydroxyl
functional groups should be maintained (OH). The corresponding hydrodynamic diameters for the
different LDBC aggregates were determined through the use of DLS shown in Table 2. The
intensity, number, polydispersity index, and zeta potentials were reported. The intensity diameter
is the average of all the aggregates, while the number diameter represents the diameter of the
majority of the aggregates formed. The two values indicated in the Table 1 under intensity correlate
with the bimodal distribution of the DLS curve that can be seen in the DLS graphs. This indicates
the presence of smaller and larger particles in the solution. Because intensity diameter favors the
largest aggregates formed, this analysis will focus primarily on the number diameter. The hydroxyl
12

and carboxylate terminated nanoparticles are similar in size when suspended in water, 214.93 nm
and 212.73 nm in diameter, respectively. These particle sizes show a large increase when compared
to the size of the amine-terminated LBDC in previous studies which is 21.3 nm in diameter. When
analyzed in PBS buffer, the carboxylate is shown to be half the size of its hydroxyl counterpart,
57.37 nm vs 131.5 nm in diameter. While the carboxylate and hydroxyl LDBCs seem to shrink in
diameter when switched from water to PBS, the amine-terminated LDBC increased from 21.3 nm
to 48.95 nm. There is also a shift in zeta potential of the nanoparticles when prepared in different
types of aqueous media. While the hydroxyl and carboxylate nanoparticles show a slight positive
charge in Milli Q water, +16.03 mV and +4.88 mV, respectively, they also exhibit a comparatively
larger negative charged surface when analysis is done in PBS buffer, -34.57mV for OH and -25.50
mV for COO-. The zeta potential of the amine-terminated LDBC was shown to have a larger
positive charge than its counterparts in water, +50.43 mV. Also, unlike the OH and COOH
versions, the amine-terminated LDBC remains positively charged in PBS buffer, +13.57 mV.

Figure 5: TEM images utilizing uranyl formate as a contrast agent for (A1) 70-DL-OH in PBS, (A2) 70-DL-OH in
water, (B) 70-DL -COOH in PBS, and (B2) 70-DL -COOH in water.
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To more clearly understand the morphology of the self-assembled nanoparticles, TEM
imaging was conducted. Uranyl formate was used as a stain to increase the contrast between the
hydrophilic and hydrophobic portions. This contrasting agent accumulates more in the dense
polyester bilayers, which causes the darker rings to be seen. This provides indirect evidence of the
aggregation of the nanoparticles into layered vesicles in both water and PBS buffer. Amphiphilic
block copolymers undergo self-assembly when placed in aqueous solution in order to minimize
the energetically unfavorable hydrophobe-water interactions. The resulting morphologies of the
self-assembled nanoparticles are primarily a result of the inherent molecular curvature and how it
influences the packing of the copolymer chains.26 Bilayered vesicles are seen in the hydroxyl and
carboxylate terminated nanoparticles, as well as the amine-terminated nanoparticles. Overall, the
size, morphology, and surface changes support potential applications in biomedical related
research. Additional studies regarding toxicity, uptake, and colloid stability are need to ensure use
in drug delivery.
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CONCLUSION
In this study, we successfully synthesized and characterized LDBCs with terminal
carboxylic acid and alcohol groups. TEM imaging shows spherical nanoparticles believed to be
bilayer vesicles for the hydroxyl and carboxylate terminated LDBCs which was also seen in the
amine-terminated LDBC. Though the hydroxyl and carboxylate nanoparticles are similar in size
to each other in Milli Q water, 214.93 nm and 212.73 nm in diameter, respectively, the carboxylate
is half the size of the hydroxyl LDBC in PBS buffer, 57.37 nm vs 131.5 nm. It is also important to
note the decrease in diameter of both the LDBCs when switching from Milli Q water to PBS.
While hydroxyl and carboxylate nanoparticles are significantly larger than the amine-terminated
counterpart, an opposite affect is seen on the size change in the amine-terminated nanoparticle
when there is a switch from Milli Q water to PBS. There is an increase in diameter from 21.3 nm
to 48.95 nm. There is also a shift in zeta potential of nanoparticles when prepared in the two
different solvents. While the hydroxyl and carboxylate nanoparticles show a slight positive charge
in Milli Q water, +16.03 mV and +4.88 mV respectively, they also exhibit a comparatively larger
negative surface charge when analysis is done in PBS buffer, -34.57mV and -25.50 mV. The zeta
potential of the amine-terminated LDBC was shown to have a larger positive charge than its
counterparts in water, +50.43 mV. Unlike the OH and COOH versions, the amine-terminated
LDBC remains positively charged in PBS buffer, +13.57 mV. This leaves room for the
investigation of how differing media, salt content, and pH affect the LDBC nanoparticles size and
charge. The success of the synthesis of these LDBC provides a synthetic route to produce selfaggregating nanoparticles with varying surface functionalities. Further studies regarding the drug
loading capacity, cell toxicity, pH studies, and cellular uptake studies will provide even more
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insight into the full potential of these molecules as drug delivery systems. These results provide
new pathways towards novel polymer nanoparticles with unique surface functionalities.
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SYNTHETIC DETAILS
SYNTHESIS OF PAMAM

Scheme S1: Synthesis of hydrophilic dendron
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(1) HO-PAMAM-G0.5
To the stirred solution of 2-aminoethan-1-ol in methanol, add 5 equivalence of methyl acrylate
dissolved in methanol dropwise under salted-ice. After the completion of the addition, allow the
solution to stir at room temperature for two days. Once completion is confirmed through 1H NMR,
the solvent is evaporated in vacuum. To remove excess reagent, the product was co-evaporated
three times with butanol, reagent alcohol, and then with methanol until complete removal was
confirmed through 1H NMR in CDCl3

(2) HO-PAMAM-G1.0
To the stirred solution of EDA dissolved in 80 equivalence of methanol, add (1) dissolved in
methanol dropwise under salted ice. After completion of the addition, allow the reaction to stir at
room temperature for 3 days. Once completion is confirmed through 1H NMR, the solvent is
evaporated in vacuum. To remove excess reagent, the product is co-evaporated three times with
butanol, reagent alcohol, and then with methanol until complete removal is confirmed through
NMR in MEOH-d4.

(3) HO-PAMAM-G1.5
To the stirred solution of (2) in methanol, add 5 equivalence of methyl acrylate dissolved in
methanol dropwise under salted-ice. After the completion of the addition, allow the solution to stir
at room temperature for two days. Once completion is confirmed through 1H NMR, the solvent is
evaporated in vacuum. To remove excess reagent, the product was co-evaporated three times with
butanol, reagent alcohol, and then with methanol until complete removal was confirmed through
1

H NMR.
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(4) HO- PAMAM-G 2.0
To the stirred solution of EDA dissolved in 80 equivalence of methanol, add (3) dissolved in
methanol dropwise under salted ice. After completion of the addition, allow the reaction to stir at
room temperature for 3 days. Once completion is confirmed through 1H NMR, the solvent is
evaporated in vacuum. To remove excess reagent, the product was co-evaporated three times with
butanol, reagent alcohol, and then with methanol until complete removal was confirmed through
1

H NMR.

(5) HO-PAMAM- TBE
To the stirred (4) dissolved in methanol, tert-butyl acrylate (TBA) was added dropwise under salted
ice. After the addition, the reaction was warmed to room temperature and allowed to stir at room
temperature for 2 days. Once completion is confirmed through 1H NMR, the solvent is evaporated.
The product is then precipitated via a separatory funnel into stirring pure hexane. The precipitation,
decanting, and air drying process was repeated twice more. This is done until the final 1H NMR
shows removal of TBA.

(6) HO-PAMAM- G2.5
To the stirred solution of (4) dissolved in methanol, add 5 equivalence of methyl acrylate dissolved
in methanol dropwise under salted-ice. After the completion of the addition, allow the solution to
stir at room temperature for 2 days. Once completion was confirmed through 1H NMR, the solvent
is evaporated in vacuum. To remove excess reagent, the product was co-evaporated three times
with butanol, reagent alcohol, and then with methanol until complete removal was confirmed
through 1H NMR.
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(7) HO- PAMAM-THP
To the stirring solution of (6) in methanol, ((tetrahydro-2H-pyran-2-yl)oxy)methanamine (THP)
dissolved in methanol was added dropwise under salted ice. After completion of the addition of
THP, the reaction was allowed to warm to room temperature and stir for 4 days. After confirmation
of completion through 1H NMR, the solvent is evaporated. The PAMAM was dissolved in a
minimal amount of DCM and precipitated into pure stirring hexane. After allowing the solution to
settle, the hexane layer is decanted and the remaining layer air-dried. This process of precipitation,
decanting, and air drying is repeated twice more.
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RING OPENING POLYMERIZATION

Scheme S2: Ring opening polymerization (ROP) with DL lactide and DBU as a catalyst

Before beginning the reaction, freeze-dry the macroinitiators (PAMAM) to ensure that there is no
water present. Under inert conditions, combine the PAMAM and DL-lactide monomer into dry
chloroform and allow to stir until dissolved. After starting material are completely dissolved, add
DBU catalyst and allow to stir for 4 hours. Once confirmation of completion through 1H NMR,
quench the reaction by adding benzoic acid and allowing it to stir for 30 minutes.
To purify the product, precipitate the crude mixture, allow the polymer to precipitate out of
solution then decant the solvent system. Each polymer needs a different solvent system as follows:
TBE- 7:3:1 ratio of hexanes to diethyl ether to methanol
THP- 7:2:1 ratio of hexanes to diethyl ether to methanol
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DEPROTECTION OF THP AND TBE

Scheme S3: Deprotection of 70-DL-THP to create 70-DL-OH

Dissolve 0.156 grams of DL-G3-THP in 6 mL of dry DCM then add 5 mL of TFA dropwise in
open air conditions. After confirmation of deprotection through 1H NMR, allow sample to dry
overnight in a vacuum oven.
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Scheme S4: Deprotection of 70-DL-TBE to create 70-DL-COOH

Dissolve 1.709 grams of DL-G3-TBE in 14 mL of dry DCM then add 1 mL of TFA dropwise in
open air conditions. Allow solution to stir for 2 hours. Add 3 mL of methanol and allow to stir for
one hour. After confirmation of deprotection through 1H NMR, allow sample to dry overnight in
vacuum oven.
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DATA
NMR SPECTRA

Figure S1:1H NMR for HO-PAMAM-G0.5 (CDCl3)

Figure S2:1H NMR for HO-PAMAM-G1.0 (MeOH-d4)
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Figure S3:1H NMR for HO-PAMAM-G1.5 (CDCl3)

Figure S4:1H NMR for HO-PAMAM-G2.0 (MeOH-d4)
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Figure S5:1H NMR for HO-PAMAM-G2.5 (CDCl3)

Figure S6:1H NMR for HO-PAMAM-G3-THP (CDCl3)
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Figure S7:1H NMR for HO-PAMAM-G3-TBE (CDCl3)

Figure S8:-1H NMR for 70-DL-COOH (CDCl3)
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Figure S9:1H NMR for 70-DL-OH (CDCl3)
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DLS SPECTRA

Figure S10:DLS spectra of 70-DL-COOH in Milli Q water; left: size distribution by intensity, right: size distribution
by volume

Figure S11:DLS spectra of 70-DL-COOH in PBS; left: size distribution by intensity, right: size distribution by volume

Figure S12:DLS spectra of 70-DL-OH in Milli Q water; left: size distribution by intensity, right: size distribution by
volume
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Figure S13:DLS spectra of 70-DL-OH in PBS; left: size distribution by intensity, right: size distribution by volume
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